SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Updated FDA Calendar of 73 Decision Dates
JNJ
|
|
|
<> The accompanying table [click to enlarge or download] includes an updated calendar of 75 expected FDA decision dates as part of the ETF Innovators [ETFI] New Drug Regulatory Catalyst Index, which includes a full slate of expected action before year-end outlined in my previous article. The last few days have been busy for antibiotics at the agency, resulting in sharply lower stock prices for Targanta Therapeutics (TARG) and Theravance (THRX). An FDA panel voted against Targanta's oritavancin, which has an upcomin>...
|
Updated FDA Calendar of 75 Decision Dates
JNJ
|
|
|
<> The accompanying table [click to enlarge or download] includes an updated calendar of 75 expected FDA decision dates, which includes a full slate of expected action before year-end outline in my previous article. The last few days have been busy for antibiotics at the agency, resulting in sharply lower stock prices for Targanta Therapeutics (TARG) and Theravance (THRX). An FDA panel voted against Targanta's oritavancin, which has an upcoming decision in early December and sent shares crashing from 8 bucks be>...
|
ETFI Global Healthcare Sector PerformIdex
JNJ
Healthcare ETFs Outpace the Market
JNJ
|
|
|
<> The accompanying table presents an analysis and statistics for the 28 healthcare ETFs listed at the Yahoo! Finance ETF Center. As a group, the healthcare ETFs outpaced the overall market in the past year by more than 10%, posting an average loss of 26.5% compared to a loss of 37.4% for the S&P 500 SPDR ETF (SPY). The best performing healthcare ETF was the Biotech HOLDRs (BBH), thanks to a buyout bid for top holding Genetech (DNA) and solid earnings results this year for the number two position, Amgen (AMGN). The top three>...
|
Updated FDA Calendar of 72 Decision Dates
JNJ
|
|
|
<> <> The accompanying table [click to enlarge image] presents an updated calendar of expected FDA decision dates, including a new NDA filing by Johnson & Johnson (JNJ) for Comfyde and recent approval for Barr Pharma's (BRL) low-dose birth control pill Lo-Seasonique. Teva Pharma (TEVA) has closed a deal with Barr's unsecured credit holders in an effort to close its proposed $7.5B acquisition by year-end, which will expand Teva's generic drug business and also add to its line-up of brand name medications through Barr's >>...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
Visit streetinsider.com
|
|
|
|
fas831
(-6.45% risk: conservative)
|
|
Johnson & Johnson vs 3M
- I have been waiting and waiting for JNJ to drop but its really dissapointing seeing such a steady stock..on the other hand is 3M who is JNJ's competito
|
More Resources
|